Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
H., Zelenski, N
A randomised phase II/III study to evaluate the efficacy and safety of orally administered Oxalobacter formigenes to treat primary hyperoxaluria
Vaccinia-related kinase 2 blunts sorafenibs efficacy against hepatocellular carcinoma by disturbing the apoptosis-autophagy balance
BPC-157 is not a therapeutic good and has not been evaluated or approved by the Therapeutic Goods Administration (TGA) or any other regulatory body
In the liver, it attaches to toxins and drug byproducts so the body can safely remove them
US$ 26.59
US$ 25.58
US$ 27.57
US$ 24.48
